Ibex Medical Analytics Enters Collaboration with AstraZeneca and Daiichi Sankyo to Develop AI-based HER2 Scoring Product

Ibex’s AI algorithm to assist pathologists with accurate and reproducible HER2 and HER2-low assessment in breast cancer diagnosis

Tel Aviv, Israel, 24 January 2023 /PRNewswire/ — Ibex Medical Analytics (Ibex), a leader in AI-powered cancer diagnostics, today announced an agreement with AstraZeneca and Daiichi Sankyo to develop, clinical validate and early adopt an AI-powered product to help pathologists. Accurate and reproducible assessment of HER2 immunohistochemistry (IHC) scoring in breast cancer patients.

(PRNewsPhoto/Ibex Medical Analytics)

Scoring of HER2 (human epidermal growth factor receptor 2) is used to determine protein expression in breast cancers that are likely to benefit from HER2-directed therapy. Currently, pathologists routinely score HER2 in tumor samples using a microscope, which can be challenging in cases of low HER2 expression because the scoring is subjective and can have different interpretations. Computational tools developed using artificial intelligence have the potential to aid pathologists in accurate and objective scoring of HER2, which may help oncologists select approved therapies to treat patients with HER2-positive or HER2-low breast cancer.

“Recognizing the critical role pathologists play in the diagnosis and treatment of cancer patients, we are pleased to partner with AstraZeneca and Daiichi Sankyo to clinically validate our automated HER2 scoring product and offer it to laboratories around the world,” it said. Joseph Mosel, co-founder and CEO of Ibex Medical Analytics. “As the most commonly diagnosed cancer in women, this collaboration will allow pathologists to use our technology to better diagnose breast cancer and ultimately improve the identification of patients eligible for HER2-directed therapy.”

Also Read :  14 best streaming Black Friday deals 2022: Top sales on services and devices

Ibex’s Galen™ Breast HER2 is an IHC scoring product that detects tumor areas based on the 2018 ASCO/CAP scoring guidelines and quantifies HER2 expression into four standard categories, 0, 1+, 2+ and 3+.1. As part of this collaboration, Ibex will work with AstraZeneca and Daiichi Sankyo to develop and clinically validate its HER2 IHC scoring product and generate evidence to support adoption of the technology.

A multi-site validation study on Galen breast HER2 included 453 breast tumors of various subtypes. The study showed that Galen’s AI algorithm provides accurate and automated HER2 scores for pathologists and was recently presented at the San Antonio Breast Cancer Symposium.2.

Beyond this collaboration, Ibex supports pathologists with AI-based diagnostic solutions that help detect and grade different types of invasive and non-invasive breast cancer and other tumor types and are used in daily practice in laboratories, hospitals and health systems around the world. Ibex’s Galen Breast Solution has demonstrated the detection and staging of several types of breast cancer and other clinically relevant features in clinical studies conducted on numerous diagnostic workflows, one of which was recently published in Nature’s peer-reviewed npj breast cancer journal.3,4.

Also Read :  NVIDIA GeForce RTX 4080 Reportedly Getting Price Cut By Mid of December To Make It Competitive Against AMD's 7900 XTX

In addition to HER2, Ibex is further expanding Galen Breast to include automated quantification of additional IHC-stained slides, such as ER, PR and Ki-67, which aims to provide pathologists with a broader set of tools for breast cancer diagnosis. With this expanded capability, Galen Breast can increase diagnostic efficiency and enable more accurate and objective scoring of breast biomarkers, improving treatment decisions and patient care.

About Ibex Medical Analysis

Ibex Medical Analytics (Ibex) is transforming cancer diagnostics with world-leading, clinical grade AI-powered solutions, empowering clinicians to provide accurate, timely and personalized cancer diagnoses for every patient. Our Galen™ suite is the first and most widely deployed AI-technology in pathology and is used as part of the daily routine, helping pathologists and providers around the world improve diagnostic quality and accuracy, implement comprehensive quality control, reduce turnaround times and with more efficient workflows. Increasing productivity. Ibex’s artificial intelligence technology is built on deep learning algorithms trained by a team of pathologists, data scientists and software engineers. For additional company information, please visit https://ibex-ai.com/ and follow us on LinkedIn and Twitter.

Also Read :  Gadget of the Week: Roomba to move

The Galen™ suite includes some solutions CE marked and registered with the UK MHRA. Solutions are for research use only (RUO). United States of America and is not approved by the FDA. For more information, including indications for use and regulatory approvals in other countries, contact Ibex Medical Analytics.

Media contact
Ibex Medical Analysis

Nechama Rosengarten
FINN Partners
[email protected]

[1] Wolf et al, Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med 142:1364-1382, 2018.

[2] Globerson et al, A fully automated artificial intelligence system for accurate and reproducible HER2 IHC scoring in breast cancer. San Antonio Breast Cancer Symposium 2022. https://ibex-ai.com/wp-content/uploads/2022/12/Ibex_HER2_at_SABCS_2022_poster.pdf

[3] Sandbank et al., Validation and Real-World Clinical Application of Artificial Intelligence Algorithms for Breast Cancer Detection in Biopsies; npj Breast Cancer 8, 129 (2022) https://doi.org/10.1038/s41523-022-00496-w

[4] Vincent-Salomon et al., AI versus microscope-assisted early diagnosis of breast biopsy: a multi-site clinical reader study. San Antonio Breast Cancer Symposium 2022. https://ibex-ai.com/wp-content/uploads/2022/12/Ibex_poster_Galen_Breast_San_Antonio.pdf

Logo – https://mma.prnewswire.com/media/1839936/Ibex_Logo.jpg

session View original content for multimedia download: https://www.prnewswire.com/news-releases/ibex-medical-analytics-enters-collaboration-with-astrazeneca-and-daiichi-sankyo-to-develop-ai-based-her2 -scoring-product-301729092.html

Source Ibex Medical Analytics Ltd


Leave a Reply

Your email address will not be published.

Related Articles

Back to top button